Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort
BACKGROUND: The Surveillance, Epidemiology, and End Results database was analyzed to explore the pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy as well as the use of adjuvant radiation in this population. METHODS: Identified were patients from 2004...
Gespeichert in:
| Veröffentlicht in: | Cancer 2010-12, Vol.116 (24), p.5757-5766 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5766 |
|---|---|
| container_issue | 24 |
| container_start_page | 5757 |
| container_title | Cancer |
| container_volume | 116 |
| creator | Schreiber, David Rineer, Justin Yu, James B. Olsheski, Michelle Nwokedi, Emmanuel Schwartz, David Choi, Kwang Rotman, Marvin |
| description | BACKGROUND:
The Surveillance, Epidemiology, and End Results database was analyzed to explore the pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy as well as the use of adjuvant radiation in this population.
METHODS:
Identified were patients from 2004 to 2006 with clinically staged T1c‐2cNx‐0M0 prostate adenocarcinoma who underwent radical prostatectomy. All patients had complete clinical and pathologic data. The use of postoperative radiation was recorded. Logistic regression analysis was performed to identify unadjusted and adjusted predictors for extraprostatic disease or positive surgical margins and for adjuvant radiation use.
RESULTS:
A total of 35,642 patients were identified. For those patients with Gleason 7 (4 + 3) and a prostate‐specific antigen (PSA) level of ≥10.1 ng/mL or Gleason 8 to 10 with any PSA level, the rate of organ‐confined disease with negative surgical margins was found to be |
| doi_str_mv | 10.1002/cncr.25561 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_816528423</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>816528423</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3911-439f0147cacbb0c663934ff13cf3cf950b3ad23a2c95f7bac569a378254f1e3c3</originalsourceid><addsrcrecordid>eNp9kduKFDEQhoMo7rh64wNIbkQRZs2h05m-XAZPsCiIgndNdTpxs2SSMUmvtq_kS1q9M653CyGVSr78VdRPyFPOzjhj4rWJJp8JpVp-j6w46_Sa8UbcJyvG2GatGvnthDwq5QpTLZR8SE4E01IrzVfkz3mEMBdfaHJ0D_UyhfTdG2p_VRvrcjn6YqFY6lKmJvjoDYQw05Aw-t92pPucSoVqqYFobKbgKu4ZxoW8fTU17WYKcaRlGor9MS3yE-piCRivpmvAfPkE1adIfaRA480ZRUy6TLk-Jg8chGKfHOMp-fr2zZft-_XFp3cftucXayM7zteN7BwOQBsww8BM28pONs5xaRyuTrFBwigkCNMppwcwqu1A6o1QjeNWGnlKXhx0sXfss9R-54uxIUC0aSr9hrdKbBohkXx5J8kZ110rdKsRfXVADQ6kZOv6ffY7yDNC_WJjv9jY39iI8LOj7jTs7HiL_vMNgedHAApO2WUcvS__OYkdNkohxw_cTx_sfEfJfvtx-_lQ_C-d3Lkp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1017962767</pqid></control><display><type>article</type><title>Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort</title><source>MEDLINE</source><source>Wiley Online Library Free Backfiles</source><source>Wiley-Blackwell Full Collection</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Schreiber, David ; Rineer, Justin ; Yu, James B. ; Olsheski, Michelle ; Nwokedi, Emmanuel ; Schwartz, David ; Choi, Kwang ; Rotman, Marvin</creator><creatorcontrib>Schreiber, David ; Rineer, Justin ; Yu, James B. ; Olsheski, Michelle ; Nwokedi, Emmanuel ; Schwartz, David ; Choi, Kwang ; Rotman, Marvin</creatorcontrib><description>BACKGROUND:
The Surveillance, Epidemiology, and End Results database was analyzed to explore the pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy as well as the use of adjuvant radiation in this population.
METHODS:
Identified were patients from 2004 to 2006 with clinically staged T1c‐2cNx‐0M0 prostate adenocarcinoma who underwent radical prostatectomy. All patients had complete clinical and pathologic data. The use of postoperative radiation was recorded. Logistic regression analysis was performed to identify unadjusted and adjusted predictors for extraprostatic disease or positive surgical margins and for adjuvant radiation use.
RESULTS:
A total of 35,642 patients were identified. For those patients with Gleason 7 (4 + 3) and a prostate‐specific antigen (PSA) level of ≥10.1 ng/mL or Gleason 8 to 10 with any PSA level, the rate of organ‐confined disease with negative surgical margins was found to be <50%. Of those with indications for adjuvant radiation, 11.1% received the treatment.
CONCLUSIONS:
This large population‐based study detailed the risk of extraprostatic extension and positive surgical margins in a broad setting across multiple regions and communities, as well as the use of adjuvant radiation for these patients. As of 2006, 11.1% of patients who had indications for adjuvant radiation received this treatment, providing a useful baseline for future patterns of care studies. Cancer 2010. © 2010 American Cancer Society.
This large population‐based study detailed the risk of extraprostatic extension and positive margins in a broad setting across multiple regions and communities, as well as the use of adjuvant radiation for these patients. As of 2006, approximately 11.1% of patients who had indications for adjuvant radiation received this treatment, providing a useful baseline for future patterns of care studies.</description><identifier>ISSN: 0008-543X</identifier><identifier>ISSN: 1097-0142</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.25561</identifier><identifier>PMID: 20737571</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma - pathology ; Adenocarcinoma - radiotherapy ; Adenocarcinoma - surgery ; adjuvant radiation ; Biological and medical sciences ; Cancer ; Humans ; Male ; Medical sciences ; Middle Aged ; Neoplasm Metastasis - radiotherapy ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; Predictive Value of Tests ; prostate cancer ; Prostatectomy ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; Prostatic Neoplasms - surgery ; radiation ; radical prostatectomy ; Radiotherapy, Adjuvant ; SEER Program ; surgery ; Surveillance, Epidemiology, and End Results program ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Cancer, 2010-12, Vol.116 (24), p.5757-5766</ispartof><rights>Copyright © 2010 American Cancer Society</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3911-439f0147cacbb0c663934ff13cf3cf950b3ad23a2c95f7bac569a378254f1e3c3</citedby><cites>FETCH-LOGICAL-c3911-439f0147cacbb0c663934ff13cf3cf950b3ad23a2c95f7bac569a378254f1e3c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.25561$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.25561$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23652455$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20737571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schreiber, David</creatorcontrib><creatorcontrib>Rineer, Justin</creatorcontrib><creatorcontrib>Yu, James B.</creatorcontrib><creatorcontrib>Olsheski, Michelle</creatorcontrib><creatorcontrib>Nwokedi, Emmanuel</creatorcontrib><creatorcontrib>Schwartz, David</creatorcontrib><creatorcontrib>Choi, Kwang</creatorcontrib><creatorcontrib>Rotman, Marvin</creatorcontrib><title>Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND:
The Surveillance, Epidemiology, and End Results database was analyzed to explore the pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy as well as the use of adjuvant radiation in this population.
METHODS:
Identified were patients from 2004 to 2006 with clinically staged T1c‐2cNx‐0M0 prostate adenocarcinoma who underwent radical prostatectomy. All patients had complete clinical and pathologic data. The use of postoperative radiation was recorded. Logistic regression analysis was performed to identify unadjusted and adjusted predictors for extraprostatic disease or positive surgical margins and for adjuvant radiation use.
RESULTS:
A total of 35,642 patients were identified. For those patients with Gleason 7 (4 + 3) and a prostate‐specific antigen (PSA) level of ≥10.1 ng/mL or Gleason 8 to 10 with any PSA level, the rate of organ‐confined disease with negative surgical margins was found to be <50%. Of those with indications for adjuvant radiation, 11.1% received the treatment.
CONCLUSIONS:
This large population‐based study detailed the risk of extraprostatic extension and positive surgical margins in a broad setting across multiple regions and communities, as well as the use of adjuvant radiation for these patients. As of 2006, 11.1% of patients who had indications for adjuvant radiation received this treatment, providing a useful baseline for future patterns of care studies. Cancer 2010. © 2010 American Cancer Society.
This large population‐based study detailed the risk of extraprostatic extension and positive margins in a broad setting across multiple regions and communities, as well as the use of adjuvant radiation for these patients. As of 2006, approximately 11.1% of patients who had indications for adjuvant radiation received this treatment, providing a useful baseline for future patterns of care studies.</description><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Adenocarcinoma - surgery</subject><subject>adjuvant radiation</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis - radiotherapy</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Predictive Value of Tests</subject><subject>prostate cancer</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Prostatic Neoplasms - surgery</subject><subject>radiation</subject><subject>radical prostatectomy</subject><subject>Radiotherapy, Adjuvant</subject><subject>SEER Program</subject><subject>surgery</subject><subject>Surveillance, Epidemiology, and End Results program</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0008-543X</issn><issn>1097-0142</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kduKFDEQhoMo7rh64wNIbkQRZs2h05m-XAZPsCiIgndNdTpxs2SSMUmvtq_kS1q9M653CyGVSr78VdRPyFPOzjhj4rWJJp8JpVp-j6w46_Sa8UbcJyvG2GatGvnthDwq5QpTLZR8SE4E01IrzVfkz3mEMBdfaHJ0D_UyhfTdG2p_VRvrcjn6YqFY6lKmJvjoDYQw05Aw-t92pPucSoVqqYFobKbgKu4ZxoW8fTU17WYKcaRlGor9MS3yE-piCRivpmvAfPkE1adIfaRA480ZRUy6TLk-Jg8chGKfHOMp-fr2zZft-_XFp3cftucXayM7zteN7BwOQBsww8BM28pONs5xaRyuTrFBwigkCNMppwcwqu1A6o1QjeNWGnlKXhx0sXfss9R-54uxIUC0aSr9hrdKbBohkXx5J8kZ110rdKsRfXVADQ6kZOv6ffY7yDNC_WJjv9jY39iI8LOj7jTs7HiL_vMNgedHAApO2WUcvS__OYkdNkohxw_cTx_sfEfJfvtx-_lQ_C-d3Lkp</recordid><startdate>20101215</startdate><enddate>20101215</enddate><creator>Schreiber, David</creator><creator>Rineer, Justin</creator><creator>Yu, James B.</creator><creator>Olsheski, Michelle</creator><creator>Nwokedi, Emmanuel</creator><creator>Schwartz, David</creator><creator>Choi, Kwang</creator><creator>Rotman, Marvin</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20101215</creationdate><title>Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort</title><author>Schreiber, David ; Rineer, Justin ; Yu, James B. ; Olsheski, Michelle ; Nwokedi, Emmanuel ; Schwartz, David ; Choi, Kwang ; Rotman, Marvin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3911-439f0147cacbb0c663934ff13cf3cf950b3ad23a2c95f7bac569a378254f1e3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Adenocarcinoma - surgery</topic><topic>adjuvant radiation</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis - radiotherapy</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Predictive Value of Tests</topic><topic>prostate cancer</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Prostatic Neoplasms - surgery</topic><topic>radiation</topic><topic>radical prostatectomy</topic><topic>Radiotherapy, Adjuvant</topic><topic>SEER Program</topic><topic>surgery</topic><topic>Surveillance, Epidemiology, and End Results program</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schreiber, David</creatorcontrib><creatorcontrib>Rineer, Justin</creatorcontrib><creatorcontrib>Yu, James B.</creatorcontrib><creatorcontrib>Olsheski, Michelle</creatorcontrib><creatorcontrib>Nwokedi, Emmanuel</creatorcontrib><creatorcontrib>Schwartz, David</creatorcontrib><creatorcontrib>Choi, Kwang</creatorcontrib><creatorcontrib>Rotman, Marvin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schreiber, David</au><au>Rineer, Justin</au><au>Yu, James B.</au><au>Olsheski, Michelle</au><au>Nwokedi, Emmanuel</au><au>Schwartz, David</au><au>Choi, Kwang</au><au>Rotman, Marvin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2010-12-15</date><risdate>2010</risdate><volume>116</volume><issue>24</issue><spage>5757</spage><epage>5766</epage><pages>5757-5766</pages><issn>0008-543X</issn><issn>1097-0142</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND:
The Surveillance, Epidemiology, and End Results database was analyzed to explore the pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy as well as the use of adjuvant radiation in this population.
METHODS:
Identified were patients from 2004 to 2006 with clinically staged T1c‐2cNx‐0M0 prostate adenocarcinoma who underwent radical prostatectomy. All patients had complete clinical and pathologic data. The use of postoperative radiation was recorded. Logistic regression analysis was performed to identify unadjusted and adjusted predictors for extraprostatic disease or positive surgical margins and for adjuvant radiation use.
RESULTS:
A total of 35,642 patients were identified. For those patients with Gleason 7 (4 + 3) and a prostate‐specific antigen (PSA) level of ≥10.1 ng/mL or Gleason 8 to 10 with any PSA level, the rate of organ‐confined disease with negative surgical margins was found to be <50%. Of those with indications for adjuvant radiation, 11.1% received the treatment.
CONCLUSIONS:
This large population‐based study detailed the risk of extraprostatic extension and positive surgical margins in a broad setting across multiple regions and communities, as well as the use of adjuvant radiation for these patients. As of 2006, 11.1% of patients who had indications for adjuvant radiation received this treatment, providing a useful baseline for future patterns of care studies. Cancer 2010. © 2010 American Cancer Society.
This large population‐based study detailed the risk of extraprostatic extension and positive margins in a broad setting across multiple regions and communities, as well as the use of adjuvant radiation for these patients. As of 2006, approximately 11.1% of patients who had indications for adjuvant radiation received this treatment, providing a useful baseline for future patterns of care studies.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>20737571</pmid><doi>10.1002/cncr.25561</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2010-12, Vol.116 (24), p.5757-5766 |
| issn | 0008-543X 1097-0142 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_816528423 |
| source | MEDLINE; Wiley Online Library Free Backfiles; Wiley-Blackwell Full Collection; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Adenocarcinoma - surgery adjuvant radiation Biological and medical sciences Cancer Humans Male Medical sciences Middle Aged Neoplasm Metastasis - radiotherapy Neoplasm Staging Nephrology. Urinary tract diseases Predictive Value of Tests prostate cancer Prostatectomy Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Prostatic Neoplasms - surgery radiation radical prostatectomy Radiotherapy, Adjuvant SEER Program surgery Surveillance, Epidemiology, and End Results program Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T16%3A52%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20pathologic%20extent%20of%20disease%20for%20clinically%20localized%20prostate%20cancer%20after%20radical%20prostatectomy%20and%20subsequent%20use%20of%20adjuvant%20radiation%20in%20a%20national%20cohort&rft.jtitle=Cancer&rft.au=Schreiber,%20David&rft.date=2010-12-15&rft.volume=116&rft.issue=24&rft.spage=5757&rft.epage=5766&rft.pages=5757-5766&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.25561&rft_dat=%3Cproquest_cross%3E816528423%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1017962767&rft_id=info:pmid/20737571&rfr_iscdi=true |